Send to

Choose Destination
Hybridoma. 1997 Aug;16(4):381-9.

Rapid development of affinity matured monoclonal antibodies using RIMMS.

Author information

Department of Molecular Sciences, Glaxo Wellcome, Research Triangle Park, NC 27709, USA.


Affinity matured murine monoclonal antibody producing cell lines can now be rapidly generated using a novel repetitive, multiple site immunization strategy designated RIMMS. RIMMS capitalizes on rapid hypermutation and affinity maturation events which occur in B cell populations localized within secondary lymphatic tissue early in response to antigenic challenges. A murine myeloma cell line, P3XBcl-2-13, stably transfected with Bcl-2, enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization. Immunizations somatic fusion, screening and isolation of affinity matured IgG secreting monoclonal antibody cell lines occur within a one month time period. By using RIMMS, we have been able to expedite the isolation of affinity matured monoclonal antibodies to numerous antigens, including a drug hapten.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center